

## REFERENCIAS

1. Lebwohl M. Psoriasis. *Lancet*. 2003;361:1197-1204.
2. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. *Acta Derm Venereol*. 2010;90:147-151.
3. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol Sci*. 2011;63(1):40-46.
4. Abuabara K, Azfar RS, Shin DB, Neiman AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. *Br J Dermatol*. 2010;163:586-592.
5. Ahlehoff O, Gislason GH, Jorgensen CH, Lindhardtsen J, Charlott M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischemic stroke: a Danish Nationwide Cohort Study. *Eu Heart J*. 2011; Aug 25. [Epub ahead of print].
6. Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. *Am J Med*. 2011;124(8):775, e1-e6.
7. Farley E, Menter A. Psoriasis: comorbidities and associations. *Giordale italiano di dermatologia e venereologia: organo ufficiale. Societa italiana di dermatologia e sifilografia*. 2011;146(1):9-15.
8. Reich K, Huffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism. TNF-857 independent of the PSORS 1 risk allele. *Arthritis Rheum*. 2007;56(6):2056-2064.
9. Muller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, et al. ["TRECID", TNFalpha related chronic inflammatory diseases – a new multiple diseases bridging concept]. *Dtsch Med Wochenschr*. 2009; 134: 2132-2136.
10. Kimball AB, Gielier U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? *J Eur Acad Dermatol Venereol*. 2010;24(9):989-1004.
11. Pereira MG, Brito L, Smith T. Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners. *Int J Behav Med*. 2012;19(3):260-9.
12. Schneider G, Heuft G, Hockmann J. Determinants of social anxiety and social avoidance in psoriasis outpatients. *J Eur Acad Dermatol Venereol*. 2011;27(3):383-386.
13. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007;370(9583):263-271.
14. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. *Br J Dermatol*. 2007;156(2):271-276.
15. Prodanovich S, Kirsner RS, Kravetz JA, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. *Arch Dermatol*. 2009; 145(6):700-703.
16. Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study a nested case-control analysis. *Br J Dermatol*. 2009;160(5):1048-1056.
17. Augustin M, Kruger K, Radke MA, Schwiippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. *Dermatology*. 2008; 217: 366-372.
18. Nast A, Reytan N, Rosumeck S, Erdmann R, Rzyany B. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. *J Eur Acad Dermatol Venereol*. 2008;22(11):1337-1342.
19. Poulin Y, Papp KA, Wasel NR, Andrew R, Fraquelli E, Bernstein G, Chan D, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. *Int J Dermatol*. 2010;49(12):1368-1375.
20. Wasel N, Poulin Y, Andrew R, Chan D, Fraquelli E, Papp K. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. *J Cutan Med Surg*. 2009;13(6):294-302.
21. Dubertret L, Mrowietz U, Ranki A, Kerkhof VD, Chimenti S, Lotti T, Schäfer G et al. European patient perspectives on the impact of psoriasis: the EU-ROPSO patient membership survey. *Br J Dermatol*. 2006; 155: 729-736.
22. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. *J Am Acad Dermatol*. 1999; 41(4): 581-583.
23. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast J. Definition and treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res*. 2011; 303: 1-10.
24. Finlay AY. Current severe psoriasis, the rule of tens. *Br J Dermatol*. 2005; 152(5): 861-867.
25. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. *Arch Dermatol*. 1989;125(2):235-240.
26. Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994; 19: 210-216.

**ABSTRACTS.** Psoriasis is a systemic inflammatory disease that affects immunologically mediated skin, nails and joints in the 2 to 3 % of world population. It was formerly considered a disease limited to the skin with few implications for the overall health of the suffering patient, but through epidemiological studies have shown that patients with psoriasis have an increased incidence of developing other chronic inflammatory conditions as rheumatoid arthritis and inflammatory bowel disease, and other conditions such as obesity, type 2 diabetes mellitus, cardiovascular disease and stroke; not to mention the link between psoriasis to psychological disorders that lead to high rates of depression and anxiety. As the focus of psoriasis as a disease limited only to the skin has been replaced by a systemic disease that must be treated with drugs in addition to controlling their skin lesions, are able to prevent the development of diseases associated with morbidity and mortality that these represent.

**Keywords:** *Consensus, psoriasis, quality of life, severity of illness index, treatment.*